Latest news with #Taltz
Yahoo
11-07-2025
- Business
- Yahoo
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
Demand for Eli Lilly's LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs have become the company's key top-line drivers. In the first quarter of 2025, they generated combined sales of $6.15 billion, accounting for around 48% of Lilly's total revenues. Investors will be most keen to know the sales numbers of these two drugs when Lilly reports second-quarter results on Aug. 7. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025. The recovery was driven by launches of the drugs in new international markets and improved supply from ramped-up production. Earlier this year, the company launched additional lower-priced vial doses of Zepbound and offered new savings for self-pay patients to boost U.S. sales. We believe that deeper penetration in the U.S. market and increased uptake in international markets are likely to have driven the growth of both drugs in the second quarter of 2025. Our model estimates for second-quarter sales of Mounjaro and Zepbound are pegged at $4.5 billion and $3.1 billion, respectively. Beyond Mounjaro and Zepbound, Lilly's broader portfolio — including the oncology drug Verzenio and immunology drug Taltz — also continues to deliver steady growth. The company's recently launched drugs, such as Omvoh and Ebglyss in immunology, Jaypirca in oncology and Kisunla in neuroscience, have all been contributing to its top-line growth. According to a research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $100 billion by 2030. Eli Lilly and Novo Nordisk NVO presently dominate this space. Mounjaro and Zepbound directly compete with Novo Nordisk's semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Like Lilly, Novo also generates a substantial portion of revenues from both drugs, which account for around 64% of its total first-quarter sales. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the obesity space. Recently, Viking started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. A mid-stage study is currently ongoing, evaluating an oral version of this obesity drug, with a data readout expected later this year. Shares of Lilly have outperformed the industry year to date, as seen in the chart below. Image Source: Zacks Investment Research From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 29.66 times forward earnings, higher than its industry's average of 15.16. However, the stock is trading below its five-year mean of 34.54. Image Source: Zacks Investment Research The bottom-line estimate for 2025 has remained consistent at $21.92, while that for 2026 has declined from $30.91 to $30.84 over the past 30 days. Image Source: Zacks Investment Research Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Globe and Mail
03-07-2025
- Business
- Globe and Mail
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
While Eli Lilly 's LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — which accounted for 48% of overall sales in the first quarter of 2025. However, Lilly also boasts a wide range of products that serve other therapeutic areas, such as neuroscience, oncology and immunology — all high-growth areas and representing significant commercial potential. Some key growth products include the oncology drug Verzenio and immunology drug Taltz, which accounted for 9% and 6% of total first-quarter sales, respectively. Sales of these blockbuster medications are being driven by increased demand — Taltz sales rose 26% year over year during the quarter, while Verzenio sales jumped 10%. Over the past couple of years, LLY's new drugs — including Omvoh and Ebglyss in immunology, Jaypirca in oncology and Kisunla in neuroscience — have all been contributing to its top-line growth. Lilly expects the potential launch of new medicines like imlunestrant for metastatic breast cancer to contribute to growth in 2025. Though Lilly's non-obesity portfolio is contributing meaningfully, investor focus largely remains on the GLP-1 products. All eyes would be on the magnitude of their sequential growth and market share gains in the upcoming second-quarter results. Our model estimates sales at around $4.46 billion for Mounjaro and $3.09 billion for Zepbound in the to-be-reported quarter. Big Pharma Diversifies Beyond Flagship Drugs While Lilly's non-obesity portfolio is gaining traction, peers like AbbVie ABBV and Merck MRK are also broadening their therapeutic reach beyond core revenue drivers. AbbVie, which already markets multiple flagship immunology drugs — Humira, Rinvoq and Skyrizi — is expanding its presence in oncology and neuroscience. In recent years, ABBV has added Epkinly, Elahere and most recently, Emrelis, bringing its total oncology therapies to five. Growth in its neuroscience segment has also been supported by increasing uptake of its migraine drugs, Ubrelvy and Qulipta. Merck, whose flagship oncology drug Keytruda accounts for nearly half of its total revenues, is expanding its late-stage pipeline to reduce dependence on the product. We believe new products like Capvaxive (pneumococcal vaccine) and Winrevair (PAH drug) have the potential to generate significant revenues over the long term. Merck recently secured the FDA's approval for long-acting RSV antibody Enflonsia for newborns, which is expected to launch later this month. LLY's Price Performance, Valuation and Estimates Shares of Lilly have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 29.45 times forward earnings, higher than its industry's average of 15.04. However, the stock is trading below its five-year mean of 34.54. Estimates for Lilly's 2025 EPS have declined from $22.23 to $21.95 in the past 60 days, and EPS estimates for 2026 have increased from $30.89 to $30.91 over the same timeframe. Eli Lilly currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
Yahoo
04-06-2025
- Business
- Yahoo
1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong sales from products outside of diabetes and obesity care. Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. And in more recent years, particularly over the past five, it's easy to point to the biggest factor driving Eli Lilly's run: The company's work in diabetes and, especially, the weight loss market. Eli Lilly is unquestionably one of the two leaders in this fast-growing field, and it appears to be gaining ground on its biggest competitor, Novo Nordisk. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects. Here's what investors should know. On May 27, Eli Lilly announced it would dish out $1 billion in cash to acquire SiteOne Therapeutics, a privately held biotech. The key asset from this transaction is STC-004, a mid-stage investigational non-opioid oral pain medicine. Though there are treatment options for chronic pain, non-opioid ones could become increasingly popular since opioid-based therapies often carry significant side effects. Meanwhile, this market is brand new. In January, Vertex Pharmaceuticals earned approval from the U.S. Food and Drug Administration for Journavx, the first non-opioid oral pain inhibitor. Eli Lilly is looking to make waves in this market with the acquisition of SiteOne Therapeutics. The transaction may or may not pan out. Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. This move is hardly out of the ordinary for Eli Lilly. One thing that sets it apart from Novo Nordisk is that, while the latter generates more than 90% of its revenue from its diabetes or obesity medicines, Eli Lilly's lineup of drugs features some major blockbusters outside this area. In the first quarter, the company's revenue grew 45% year over year to $12.73 billion. Eli Lilly's cancer drug Verzenio racked up $1.2 billion in sales, up 10% year over year. The company's immunosuppressant, Taltz, generated $762 million in revenue, a 26% increase over the year-ago period. Eli Lilly's sales outside of diabetes and obesity products accounted for almost 28% of its top line. That might not exactly be peak diversification, but Eli Lilly fares better than its eternal rival, Novo Nordisk, in this department. Furthermore, the company's newer products also feature several that fall outside its core area of expertise. These include Kisunla in Alzheimer's disease, Jaypirca in oncology, and Ebglyss, an eczema treatment. The same can be said about Eli Lilly's pipeline. Consider the company's investigational gene therapy for genetic deafness, as well as its several dozen programs in oncology. To be clear, Eli Lilly's diabetes and weight management medicines should continue occupying the role of main growth drivers. In the first quarter, Mounjaro's revenue soared by 113% year over year to $3.8 billion. Zepbound's sales came in at $2.3 billion, representing a 347% increase compared to the first quarter of 2024. Neither has peaked yet. Considering analyst projections for the GLP-1 market, they will continue growing their sales at an incredible clip at least through the end of the decade. And there is more where that came from, too. Eli Lilly is developing newer medicines in this area. The company's investigational oral GLP-1 therapy, orforglipron, recently aced a phase 3 study. According to management, the drugmaker has a total of 11 obesity pipeline candidates. So, Eli Lilly's work in this field will remain one of the major keys to its success. Perhaps it is what will get many investors nowadays interested in the stock. However, Eli Lilly is also a diversified pharmaceutical giant with a strong portfolio of medicines and promising candidates in oncology, immunology, and other areas. So, even with mounting competition in the GLP-1 market, Eli Lilly remains attractive, not just because it is likely to develop better anti-obesity medicines than most of its competitors, but because it is a leader in other markets as well. That's another excellent reason to invest in Eli Lilly and hold on to its shares for a long time. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Underrated Reason to Buy This Market-Beating Stock was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Eli Lilly and Company's LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of key drugs, Mounjaro, Zepbound, Jardiance, and Taltz beat estimates, while only Verzenio missed expectations. Lilly's new products also contributed to sales growth. Trulicity sales continued to decline in the quarter. Lilly maintained its sales guidance for 2025 while lowering its earnings expectations to account for the charges recorded in the first quarter related to the acquisition of the Scorpion Therapeutics PI3Kα inhibitor program. Excluding these charges, the company's EPS guidance was unchanged. Despite the better-than-expected sales performance, Lilly's stock nosedived 11% the day it announced the first-quarter results. However, this was not just for the earnings miss and the EPS guidance cut. The stock also took a hit because CVS Caremark, a major pharmacy benefit manager ('PBM'), announced a partnership with rival Novo Nordisk NVO to make NVO's Wegovy its preferred GLP-1 therapy for weight loss, effective July 1. NVO also recently announced partnerships with telehealth providers Hims & Hers Health to offer Wegovy at a discounted price to cash-paying patients. However, we believe the stock's sell-off following the first-quarter earnings was an overreaction. Let's understand the company's strengths and weaknesses to better analyze how to play the stock amid the recent price dip. Lilly has a strong portfolio of medicines to treat diabetes and other cardiometabolic diseases and its cardiometabolic business is its most successful business, particularly with the success of its popular tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. Despite being on the market for less than three years, Mounjaro and Zepbound became key top-line drivers for Lilly, with demand rising rapidly. Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company's total revenues. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025, driven by launches of the drugs in new international markets and improved supply from ramped-up production. Both drugs enjoy increasing market share inthe United States. Mounjaro is the market leader in new prescription within type II diabetes incretin analogs. In the first quarter, Zepbound held the leading market share in the anti-obesity market, with total prescription and new prescription reaching 60% and 74% respectively. We believe that increased uptake in outside U.S. markets and deeper penetration into the U.S. market will continue to drive Mounjaro and Zepbound's growth in future quarters. Mounjaro was recently launched in China, and Lilly expects to increase commercial launches in the country in the second half of 2025 as supply improves. Lilly also launched Mounjaro in India and Mexico recently and plans to continue with additional country launches throughout 2025. Approvals for new indications can also drive sales of Mounjaro and Zepbound higher. In late December, the FDA approved Zepbound for its second indication, moderate-to-severe obstructive sleep apnea in adults with obesity. In addition, LLY filed tirzepatide for heart failure, which further expands the opportunity for the candidate. It also expects to announce data from a cardiovascular outcome study on tirzepatide this year. In 2025, Lilly launched additional Zepbound lower-priced vial doses and offered new savings for self-pay patients to boost sales. Other than Mounjaro and Zepbound, Lilly has gained approvals for some other new drugs in the past couple of years. These include Omvoh for ulcerative colitis and Crohn's disease, BTK inhibitor Jaypirca for mantle cell lymphoma and chronic lymphocytic leukemia, Ebglyss for moderate-to-severe atopic dermatitis and Kisunla (donanemab) for early symptomatic Alzheimer's disease. Its new drugs are also contributing to its top-line growth. Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025. It also expects the potential launch of new medicines like imlunestrant for metastatic breast cancer to contribute to growth in 2025. Lilly is also making rapid pipeline progress in obesity, diabetesand cancer, with several key mid and late-stage data-readouts expected this year. Lilly is investing broadly in obesity and has several new molecules currently in clinical development. These include two late-stage candidates, orforglipron, an oral GLP-1 small molecule, and retatrutide, a GGG tri-agonist and some mid-stage candidates, bimagrumab, eloralintide and mazdutide. Data from the first of the seven phase III studies on orforglipron in type II diabetes and obesity was announced in April 2025. In the study, orforglipron lowered A1C by an average of 1.3% - 1.6% across doses and also reduced weight by an average of 16lb (7.9%) at the highest dose. Lilly expects to report additional results from the phase III ACHIEVE clinical program, as well as data from the phase III ATTAIN clinical program evaluating orforglipron for obesity, later this year. It plans to file regulatory applications for orforglipron in obesity by the end of this year and for type II diabetes in the first half of 2026. The obesity market is heating up and is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk presently dominate the market. Several companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and type-II diabetes, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Phase III studies with the subcutaneous formulation of VK2735 are on track to begin in the second quarter. AMGN and VKTX's products can pose strong competition to Mounjaro/Zepbound and NVO's Ozempic/Wegovy in the future. Others like Roche, Merck and AbbVie are also looking to enter the obesity space by in-licensing obesity candidates from smaller biotechs, which could threaten Novo Nordisk and Eli Lilly's dominance in the market. Lilly's stock has declined 3.2% so far this year, underperforming the industry's decrease of 2.4% Image Source: Zacks Investment Research The stock is trading at a premium to the industry, as seen in the chart below. Image Source: Zacks Investment Research Estimates for Lilly's 2025 earnings have declined from $23.49 to $22.20 per share in the past 30 days, while those for 2026 have declined from $31.28 to $30.83 over the same timeframe. Image Source: Zacks Investment Research Lilly is battling several challenges at present. Sales of its key medicine, Trulicity, are declining in the United States due to competitive dynamics, including Mounjaro switches and supply constraints. Prices of most of Lilly's products are declining in the United States, including Mounjaro and Zepbound, primarily due to changes to estimates for rebates and discounts. Lilly's U.S. net price has declined every year since 2021. In 2025, Lilly expects a mid-to-high single-digit percentage price decline, including U.S. Part D changes. Potential competition in the GLP-1 diabetes/obesity market is another headwind. Trump and the Republican government also continue to stress on the control of drug prices with the latest attempt being his 'most favored nations' policy.' The potential impact of tariffs imposed by the United States and some other countries is a concern. Though Lilly's 2025 earnings guidance absorbs the impact of tariffs already in place, expanding tariffs in other geographies or increases in retaliatory tariffs would hurt the financial outlook. Though pharmaceuticals have been exempted from tariffs this time around, they could well be Trump's target in the next round, considering the President's goal to shift pharmaceutical production back to the United States, mostly from European and Asian countries. Also, CVS' deal with NVO, which can hurt Zepbound's market share, has raised investor concerns about such PBM formulary changes in the obesity space. However, regarding the deal, Lilly's CEO, Dave Ricks, said that Lilly was not interested in such one-on-one deals and was more focused on expanding access for Zepbound. He does not expect CVS' decision to exclude Zepbound in favor of Wegovy to hurt Lilly's revenues. Looking at the brighter side, Lilly's tremendous success with Mounjaro and Zepbound has made it the largest drugmaker with a market cap of more than $700 billion. Lilly's stock has gone up by almost 400% in the past five years, mainly due to its successful new drug launches, particularly Mounjaro and Zepbound, and its solid pipeline potential. In 2025, Lilly expects to record revenues in the range of $58.0 billion to $61.0 billion, indicating an impressive 32% year-over-year growth. Lilly's revenue growth is being driven by higher demand for Mounjaro, Zepbound, Verzenio, and others, which is making up for the decline in sales from Trulicity. LLY returned $2.5 billion to shareholders in the first quarter via share repurchases and dividends. Despite an expensive valuation and declining estimates, we suggest investors who own this Zacks Rank #3 (Hold) company retain it as it has solid growth prospects despite some near-term headwinds. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Lilly's stock is trading below its 5-year mean now. The recent dip in price can be used as a buying opportunity for long-term investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly. Let's look deeper into the pharmaceutical giant's latest clinical win and what it could mean for investors. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The active ingredient in Zepbound is tirzepatide, the first dual GLP-1/GIP agonist to earn approval from the U.S. Food and Drug Administration. Like its biggest rival on the market, Wegovy, Zepbound is administered via subcutaneous injection once a week. However, some patients don't like to poke needles into their skin and would prefer an oral pill instead, even if they have to take it daily. That's why many drugmakers have been looking to develop an effective oral weight loss option, and Eli Lilly might have just done it. In a phase 3 study, orforglipron, a once-daily weight management candidate, delivered excellent results in patients with type 2 diabetes. The highest dose of the therapy led to a mean weight loss of 7.9% in the trial, along with a 1.5% decrease in A1C levels over 40 weeks. As Lilly pointed out, orforglipron's performance was consistent with that of injectable GLP-1 medicines. Since orforglipron is an oral pill, it will be easier (and cheaper) to manufacture in large quantities and launch in markets worldwide. That would be a meaningful advantage even if companies weren't dealing with tariff-related expenses that could increase their manufacturing costs. And since orforglipron's efficacy is consistent with that of existing injected medicines, it should capture a decent share of the market. So we can expect orforglipron to become an important part of Eli Lilly's lineup. However, there are plenty of other reasons to invest in the stock. Lilly has outperformed the market in recent years due to its progress in diabetes and weight loss, while some of its older products continue to perform exceptionally well. Consider Verzenio, a cancer drug. Last year, its sales soared by 37% year over year to $5.3 billion. Taltz, Lilly's immunosuppressant, reported revenue of $3.3 billion last year, 18% higher than the year-ago period. Eli Lilly isn't just a diabetes or a weight loss company. These products -- and some of the newer approvals the company has earned -- show that. One of its more impressive achievements is the launch of Kisunla, a therapy for Alzheimer's disease (AD) -- an area that earned the nickname of a "graveyard" for investigational medicines, considering the large number of clinical failures. However, Lilly succeeded where the overwhelming majority of drugmakers failed, and Kisunla should be an important growth driver for a while. Beyond any single medicine, though, Eli Lilly's greatest strength is proving to be its innovative abilities. Whether it's in diabetes, weight loss, Alzheimer's disease, immunology, or oncology, the pharmaceutical leader has had significant clinical and regulatory wins in recent years, adding several blockbusters -- or future blockbusters -- to its lineup. That's why revenue and earnings have recently grown rapidly, and it should maintain that pace: Additionally, Lilly is an excellent dividend-paying stock. Its forward yield of 0.7% doesn't look particularly attractive -- the average for the S&P 500 is 1.3%. However, the company has increased its dividend by 200% in the past decade. And with a conservative payout ratio of 44%, it has room to increase its dividend even further. Eli Lilly's shares jumped on the orforglipron news, and are now in the green for the year. But there's plenty of upside left for the stock, for those willing to hold onto its shares through volatility. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $561,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $606,106!* Now, it's worth noting Stock Advisor's total average return is 811% — a market-crushing outperformance compared to 153% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Prosper Junior Bakiny has positions in Eli Lilly. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug was originally published by The Motley Fool Sign in to access your portfolio
